Tanvex BioPharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2020
Cash & Equivalents	570.97	376.96	380.75	786.23	2,223	2,069	Upgrade
Cash & Short-Term Investments	570.97	376.96	380.75	786.23	2,223	2,069	Upgrade
Cash Growth	-45.13%	-1.00%	-51.57%	-64.63%	7.46%	-14.78%	Upgrade
Accounts Receivable	186.65	0.07	9.4	0.33	2.52	-	Upgrade
Other Receivables	10.12	31.58	27.43	27.36	25.31	25.57	Upgrade
Receivables	196.77	31.65	36.83	27.69	27.84	25.57	Upgrade
Inventory	304.56	217.84	108.29	170.84	90.33	50.08	Upgrade
Prepaid Expenses	82.12	49.18	78.35	58.95	60.85	119.25	Upgrade
Total Current Assets	1,180	675.62	604.21	1,044	2,402	2,264	Upgrade
Property, Plant & Equipment	2,184	1,827	1,928	2,151	2,114	1,906	Upgrade
Other Intangible Assets	3,244	7.07	3.38	12.07	10.17	11.96	Upgrade
Other Long-Term Assets	87.04	225.3	227.67	213.47	187.58	190.98	Upgrade
Total Assets	6,894	2,735	2,763	3,420	4,714	4,373	Upgrade
Accounts Payable	17.12	-	-	-	-	-	Upgrade
Accrued Expenses	-	134.27	-	115.93	137.49	210.99	Upgrade
Current Portion of Long-Term Debt	-	-	-	-	-	54.77	Upgrade
Current Portion of Leases	165.85	160.01	163.45	124.65	88.75	65.74	Upgrade
Current Income Taxes Payable	26.89	-	-	-	-	-	Upgrade
Current Unearned Revenue	95.87	11.11	6.91	28.07	-	-	Upgrade
Other Current Liabilities	237.07	42.75	193.38	34.63	22.28	21.6	Upgrade
Total Current Liabilities	542.79	348.14	363.73	303.29	248.51	353.1	Upgrade
Long-Term Debt	-	-	-	-	-	35.53	Upgrade
Long-Term Leases	1,370	1,488	1,568	1,715	1,670	1,363	Upgrade
Long-Term Unearned Revenue	107.92	5.47	10.23	-	-	-	Upgrade
Other Long-Term Liabilities	-	-	-	10.47	-	-	Upgrade
Total Liabilities	2,020	1,842	1,942	2,028	1,919	1,752	Upgrade
Common Stock	2,387	1,641	1,340	3,527	3,525	3,116	Upgrade
Additional Paid-In Capital	17,909	13,567	12,431	11,061	10,988	9,653	Upgrade
Retained Earnings	-14,943	-14,136	-12,755	-12,969	-11,327	-9,784	Upgrade
Comprehensive Income & Other	-479.23	-177.94	-194.17	-227.09	-390.12	-364.04	Upgrade
Shareholders' Equity	4,874	893.31	821.11	1,391	2,795	2,621	Upgrade
Total Liabilities & Equity	6,894	2,735	2,763	3,420	4,714	4,373	Upgrade
Total Debt	1,535	1,648	1,732	1,839	1,759	1,519	Upgrade
Net Cash (Debt)	-964.41	-1,271	-1,351	-1,053	463.95	549.19	Upgrade
Net Cash Growth	-	-	-	-	-15.52%	-73.66%	Upgrade
Net Cash Per Share	-4.89	-8.19	-10.48	-8.95	4.27	6.14	Upgrade
Filing Date Shares Outstanding	238.68	164.07	133.96	117.64	117.57	103.95	Upgrade
Total Common Shares Outstanding	238.68	164.07	133.96	117.64	117.57	103.95	Upgrade
Working Capital	637.55	327.48	240.48	740.43	2,153	1,910	Upgrade
Book Value Per Share	20.42	5.44	6.13	11.83	23.77	25.21	Upgrade
Tangible Book Value	1,630	886.24	817.73	1,379	2,785	2,609	Upgrade
Tangible Book Value Per Share	6.83	5.40	6.10	11.73	23.68	25.10	Upgrade
Machinery	-	1,089	982.54	975.18	889.53	884.87	Upgrade
Construction In Progress	-	44.34	83.71	72.82	53.8	48.78	Upgrade
Leasehold Improvements	-	509.94	415.69	388.62	318.95	322.42	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.